.Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IA06_Technetium99mtcArcitumom.Technetium99mtcArcitumom .Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IA06_Technetium99mtcArcitumom.Technetium99mtcArcitumom| name: | Technetium99mtcArcitumomab |
| ATC code: | V09IA06 | route: | intravenous |
| n-compartments | 1 |
Technetium (99mTc) arcitumomab is a radiopharmaceutical agent composed of a murine monoclonal antibody (arcitumomab) labeled with the radionuclide technetium-99m. It binds to carcinoembryonic antigen (CEA) and is used in the diagnosis of colorectal cancer through gamma imaging to localize CEA-expressing tumors. It is not widely used today due to the development of more advanced imaging agents.
No peer-reviewed publications with detailed pharmacokinetic parameters (e.g., clearance, volume of distribution) for technetium (99mTc) arcitumomab in humans are available as of 2024-06. Dosing is reported to be typically intravenous, with imaging conducted 2–5 hours post-injection.